Immunotherapy before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving a combination of immunotherapy drugs (pembrolizumab, N-803, and possibly PD-L1 t-haNK cells) before surgery can help treat head and neck cancer that has not been treated yet. It is for people whose cancer is p16-negative (a specific marker) and is at an intermediate or high risk of coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck squamous cell carcinoma that has not been treated before and is at stage II, III, or IV.
- Your tumor is p16-negative if it started in the oropharynx (back of the throat).
- You are 18 years or older.
- You are well enough to have daily activities (ECOG score 0 or 1).
- You are scheduled to have surgery to remove the cancer.
- You are willing to have biopsies (small tissue samples) taken before and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests pembrolizumab and an investigational drug (IO102-103) given before surgery for certain non-bulky head and neck squamous cell cancers. The goal is to shrink the cancer and improve chances of cure by treating it before the operation.
This trial tests an immunotherapy drug (anti-PD-1) given before surgery for head and neck cancer that has come back or spread. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
Hear when a new Stage II Squamous Cell Carcinoma of the Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.